Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model

Gerald K. Chege, Wendy A. Burgers, Helen Stutz, Ann E. Meyers, Rosamund Chapman, Agano Kiravu, Rubina Bunjun, Enid G. Shephard, William R. Jacobs, Edward P. Rybicki, Anna Lise Williamson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We previously reported that a recombinant pantothenate auxotroph of Mycobacterium bovis BCG expressing human immunodeficiency virus type 1 (HIV-1) subtype C Gag (rBCGpan-Gag) efficiently primes the mouse immune system for a boost with a recombinant modified vaccinia virus Ankara (rMVA) vaccine. In this study, we further evaluated the immunogenicity of rBCGpan- Gag in a nonhuman primate model. Two groups of chacma baboons were primed or mock primed twice with either rBCGpan- Gag or a control BCG. Both groups were boosted with HIV-1 Pr55gag virus-like particles (Gag VLPs). The magnitude and breadth of HIV-specific cellular responses were measured using a gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay, and the cytokine profiles and memory phenotypes of T cells were evaluated by polychromatic flow cytometry. Gag-specific responses were detected in all animals after the second inoculation with rBCGpan-Gag. Boosting with Gag VLPs significantly increased the magnitude and breadth of the re ponses in the baboons that were primed with rBCGpan-Gag. These responses targeted an average of 12 Gag peptides per animal, compared to an average of 3 peptides per animal for the mockprimed controls. Robust responses of Gag-specific polyfunctional T cells capable of simultaneously producing IFN-γ, tumor necrosis alpha (TNF-α), and interleukin-2 (IL-2) were detected in the rBCGpan-Gag-primed animals. Gag-specific memory T cells were skewed toward a central memory phenotype in both CD8+ and CD8+ T cell populations. These data show that the rBCGpan-Gag prime and Gag VLP boost vaccine regimen is highly immunogenic, inducing a broad and polyfunctional central memory T cell response. This report further indicates the feasibility of developing a BCG-based HIV vaccine that is safe for childhood HIV immunization.

Original languageEnglish (US)
Pages (from-to)5151-5160
Number of pages10
JournalJournal of virology
Volume87
Issue number9
DOIs
StatePublished - May 1 2013

Fingerprint

Mycobacterium bovis BCG
AIDS Vaccines
Mycobacterium bovis
Primates
Immunity
T-lymphocytes
immunity
animal models
vaccines
T-Lymphocytes
Human immunodeficiency virus 1
HIV-1
animals
Papio ursinus
Vaccines
virus-like particle vaccines
HIV
peptides
Phenotype
auxotrophs

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Insect Science
  • Virology

Cite this

Chege, G. K., Burgers, W. A., Stutz, H., Meyers, A. E., Chapman, R., Kiravu, A., ... Williamson, A. L. (2013). Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. Journal of virology, 87(9), 5151-5160. https://doi.org/10.1128/JVI.03178-12

Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. / Chege, Gerald K.; Burgers, Wendy A.; Stutz, Helen; Meyers, Ann E.; Chapman, Rosamund; Kiravu, Agano; Bunjun, Rubina; Shephard, Enid G.; Jacobs, William R.; Rybicki, Edward P.; Williamson, Anna Lise.

In: Journal of virology, Vol. 87, No. 9, 01.05.2013, p. 5151-5160.

Research output: Contribution to journalArticle

Chege, GK, Burgers, WA, Stutz, H, Meyers, AE, Chapman, R, Kiravu, A, Bunjun, R, Shephard, EG, Jacobs, WR, Rybicki, EP & Williamson, AL 2013, 'Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model', Journal of virology, vol. 87, no. 9, pp. 5151-5160. https://doi.org/10.1128/JVI.03178-12
Chege, Gerald K. ; Burgers, Wendy A. ; Stutz, Helen ; Meyers, Ann E. ; Chapman, Rosamund ; Kiravu, Agano ; Bunjun, Rubina ; Shephard, Enid G. ; Jacobs, William R. ; Rybicki, Edward P. ; Williamson, Anna Lise. / Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. In: Journal of virology. 2013 ; Vol. 87, No. 9. pp. 5151-5160.
@article{80ab9a62dd0047c4aaf07222c03211d9,
title = "Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model",
abstract = "We previously reported that a recombinant pantothenate auxotroph of Mycobacterium bovis BCG expressing human immunodeficiency virus type 1 (HIV-1) subtype C Gag (rBCGpan-Gag) efficiently primes the mouse immune system for a boost with a recombinant modified vaccinia virus Ankara (rMVA) vaccine. In this study, we further evaluated the immunogenicity of rBCGpan- Gag in a nonhuman primate model. Two groups of chacma baboons were primed or mock primed twice with either rBCGpan- Gag or a control BCG. Both groups were boosted with HIV-1 Pr55gag virus-like particles (Gag VLPs). The magnitude and breadth of HIV-specific cellular responses were measured using a gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay, and the cytokine profiles and memory phenotypes of T cells were evaluated by polychromatic flow cytometry. Gag-specific responses were detected in all animals after the second inoculation with rBCGpan-Gag. Boosting with Gag VLPs significantly increased the magnitude and breadth of the re ponses in the baboons that were primed with rBCGpan-Gag. These responses targeted an average of 12 Gag peptides per animal, compared to an average of 3 peptides per animal for the mockprimed controls. Robust responses of Gag-specific polyfunctional T cells capable of simultaneously producing IFN-γ, tumor necrosis alpha (TNF-α), and interleukin-2 (IL-2) were detected in the rBCGpan-Gag-primed animals. Gag-specific memory T cells were skewed toward a central memory phenotype in both CD8+ and CD8+ T cell populations. These data show that the rBCGpan-Gag prime and Gag VLP boost vaccine regimen is highly immunogenic, inducing a broad and polyfunctional central memory T cell response. This report further indicates the feasibility of developing a BCG-based HIV vaccine that is safe for childhood HIV immunization.",
author = "Chege, {Gerald K.} and Burgers, {Wendy A.} and Helen Stutz and Meyers, {Ann E.} and Rosamund Chapman and Agano Kiravu and Rubina Bunjun and Shephard, {Enid G.} and Jacobs, {William R.} and Rybicki, {Edward P.} and Williamson, {Anna Lise}",
year = "2013",
month = "5",
day = "1",
doi = "10.1128/JVI.03178-12",
language = "English (US)",
volume = "87",
pages = "5151--5160",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "9",

}

TY - JOUR

T1 - Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model

AU - Chege, Gerald K.

AU - Burgers, Wendy A.

AU - Stutz, Helen

AU - Meyers, Ann E.

AU - Chapman, Rosamund

AU - Kiravu, Agano

AU - Bunjun, Rubina

AU - Shephard, Enid G.

AU - Jacobs, William R.

AU - Rybicki, Edward P.

AU - Williamson, Anna Lise

PY - 2013/5/1

Y1 - 2013/5/1

N2 - We previously reported that a recombinant pantothenate auxotroph of Mycobacterium bovis BCG expressing human immunodeficiency virus type 1 (HIV-1) subtype C Gag (rBCGpan-Gag) efficiently primes the mouse immune system for a boost with a recombinant modified vaccinia virus Ankara (rMVA) vaccine. In this study, we further evaluated the immunogenicity of rBCGpan- Gag in a nonhuman primate model. Two groups of chacma baboons were primed or mock primed twice with either rBCGpan- Gag or a control BCG. Both groups were boosted with HIV-1 Pr55gag virus-like particles (Gag VLPs). The magnitude and breadth of HIV-specific cellular responses were measured using a gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay, and the cytokine profiles and memory phenotypes of T cells were evaluated by polychromatic flow cytometry. Gag-specific responses were detected in all animals after the second inoculation with rBCGpan-Gag. Boosting with Gag VLPs significantly increased the magnitude and breadth of the re ponses in the baboons that were primed with rBCGpan-Gag. These responses targeted an average of 12 Gag peptides per animal, compared to an average of 3 peptides per animal for the mockprimed controls. Robust responses of Gag-specific polyfunctional T cells capable of simultaneously producing IFN-γ, tumor necrosis alpha (TNF-α), and interleukin-2 (IL-2) were detected in the rBCGpan-Gag-primed animals. Gag-specific memory T cells were skewed toward a central memory phenotype in both CD8+ and CD8+ T cell populations. These data show that the rBCGpan-Gag prime and Gag VLP boost vaccine regimen is highly immunogenic, inducing a broad and polyfunctional central memory T cell response. This report further indicates the feasibility of developing a BCG-based HIV vaccine that is safe for childhood HIV immunization.

AB - We previously reported that a recombinant pantothenate auxotroph of Mycobacterium bovis BCG expressing human immunodeficiency virus type 1 (HIV-1) subtype C Gag (rBCGpan-Gag) efficiently primes the mouse immune system for a boost with a recombinant modified vaccinia virus Ankara (rMVA) vaccine. In this study, we further evaluated the immunogenicity of rBCGpan- Gag in a nonhuman primate model. Two groups of chacma baboons were primed or mock primed twice with either rBCGpan- Gag or a control BCG. Both groups were boosted with HIV-1 Pr55gag virus-like particles (Gag VLPs). The magnitude and breadth of HIV-specific cellular responses were measured using a gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay, and the cytokine profiles and memory phenotypes of T cells were evaluated by polychromatic flow cytometry. Gag-specific responses were detected in all animals after the second inoculation with rBCGpan-Gag. Boosting with Gag VLPs significantly increased the magnitude and breadth of the re ponses in the baboons that were primed with rBCGpan-Gag. These responses targeted an average of 12 Gag peptides per animal, compared to an average of 3 peptides per animal for the mockprimed controls. Robust responses of Gag-specific polyfunctional T cells capable of simultaneously producing IFN-γ, tumor necrosis alpha (TNF-α), and interleukin-2 (IL-2) were detected in the rBCGpan-Gag-primed animals. Gag-specific memory T cells were skewed toward a central memory phenotype in both CD8+ and CD8+ T cell populations. These data show that the rBCGpan-Gag prime and Gag VLP boost vaccine regimen is highly immunogenic, inducing a broad and polyfunctional central memory T cell response. This report further indicates the feasibility of developing a BCG-based HIV vaccine that is safe for childhood HIV immunization.

UR - http://www.scopus.com/inward/record.url?scp=84876330020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876330020&partnerID=8YFLogxK

U2 - 10.1128/JVI.03178-12

DO - 10.1128/JVI.03178-12

M3 - Article

C2 - 23449790

AN - SCOPUS:84876330020

VL - 87

SP - 5151

EP - 5160

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 9

ER -